• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Pfizer wins court challenge on Lipitor

      Posted AtMSNBC.com

      Pfizer, the world's largest pharmaceutical company, received an important boost on Wednesday when a British court rebuffed a legal challenge by a generic rival to break the patent on its blockbusting heart drug Lipitor.

      Judge Nicholas Pumfrey in the High Court in London rejected claims by Ranbaxy of India that its patents on Lipitor were invalid, in a move that protects the Pfizer drug in the UK until 2011, subject to appeals. Hank McKinnell, Pfizer's chairman and chief executive, said: "This is an important victory not only for Pfizer but for all innovators pursuing high-risk medical discoveries that benefit current and future generations of patients around the world."

      The decision - news of which pushed up Pfizer's share price by up to 5 per cent - had been closely watched by investors, at a time when multinational drugs companies are facing growing threats to their sales from the expiry of patents over the coming years.

      The pressure has been further inflamed by growing aggression by generic companies in recent years to launch legal challenges to patents long before they expire in an effort to enter the market, forcing down prices and margins.

      The London court ruling marked a significant victory after Pfizer lost a similar legal challenge on its drug earlier this year in Austria. It comes ahead of a far more important litigation launched by Ranbaxy on Lipitor in its largest market in the US, where a decision is anticipated by the end of this year.

      Lipitor is the world's best-selling prescription drug, with sales estimated to reach $12bn this year, of which the UK represents 7 per cent of the market. It accounts for about one fifth of Pfizer's annual sales, and represented a powerful target for generics companies.

      The High Court upheld Pfizer's defence that it held a valid "genus" patent until 2011 on the underlying chemical compound in Lipitor. However, in a partial victory for Ranbaxy and its co-litigation Arrow, the judge ruled that a second Pfizer "species" patent covering the calcium salt for the drug until 2010 was invalid.

      Both companies said that they would appeal the judgement.

      Pfizer said the UK ruling had no bearing on the forthcoming US judgement, and stressed that it would continue to uphold its Lipitor patents wherever they were challenged.

      Lipitor, which was introduced in 1997, reduces Cholesterol in the blood, and has been prescribed to 18m patients in the US alone. It is approved for use in more than 70 countries.

      October 12, 2005


       

      Share this Article!

    Back to top^